Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Benzoic acid, 4-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-propynyl]-, methyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

203453-81-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Benzoic acid, 4-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-propyn-1-yl]-, methyl ester

    Cas No: 203453-81-0

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 203453-81-0 Structure
  • Basic information

    1. Product Name: Benzoic acid, 4-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-propynyl]-, methyl ester
    2. Synonyms:
    3. CAS NO:203453-81-0
    4. Molecular Formula: C16H19NO4
    5. Molecular Weight: 289.331
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 203453-81-0.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Benzoic acid, 4-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-propynyl]-, methyl ester(CAS DataBase Reference)
    10. NIST Chemistry Reference: Benzoic acid, 4-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-propynyl]-, methyl ester(203453-81-0)
    11. EPA Substance Registry System: Benzoic acid, 4-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-propynyl]-, methyl ester(203453-81-0)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 203453-81-0(Hazardous Substances Data)

203453-81-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 203453-81-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,4,5 and 3 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 203453-81:
(8*2)+(7*0)+(6*3)+(5*4)+(4*5)+(3*3)+(2*8)+(1*1)=100
100 % 10 = 0
So 203453-81-0 is a valid CAS Registry Number.

203453-81-0Relevant articles and documents

Selective Fluoromethyl Couplings of Alkynes via Nickel Catalysis

Li, Huan,Wang, Fang,Zhu, Shengqing,Chu, Lingling

, (2022/01/20)

We describe here a Ni-catalyzed intermolecular carbo-fluoromethylation of alkynes with aliphatic halides and fluoromethyl halides (BrCF2H and ICH2F) in the presence of zinc, enabling the facile and selective access to a diverse range of biologically valuable CF2H/CH2F-incorporated alkenes with excellent regio- and stereoselectivity. Notably, merging intramolecular radical cyclization with fluoromethyl coupling enables the expedient constructions of CF2H/CH2F-incorporated lactones and lactams with high efficiency and selectivity. Mechanistic studies disclose that this catalytic protocol proceeds via a radical addition to an alkyne followed by selective coupling with the fluoromethyl unit.

Structure–Activity Relationship of Propargylamine-Based HDAC Inhibitors

Wünsch, Matthias,Senger, Johanna,Schultheisz, Philipp,Schwarzbich, Sabrina,Schmidtkunz, Karin,Michalek, Carmela,Kla?, Michaela,Goskowitz, Stefanie,Borchert, Philipp,Praetorius, Lucas,Sippl, Wolfgang,Jung, Manfred,Sewald, Norbert

supporting information, p. 2044 - 2053 (2017/12/07)

As histone deacetylases (HDACs) play an important role in the treatment of cancer, their selective inhibition has been the subject of various studies. These continuous investigations have given rise to a large collection of pan- and selective HDAC inhibitors, containing diverse US Food and Drug Administration (FDA)-approved representatives. In previous studies, a class of alkyne-based HDAC inhibitors was presented. We modified this scaffold in two previously neglected regions and compared their cytotoxicity and affinity toward HDAC1, HDAC6, and HDAC8. We were able to show that R-configured propargylamines contribute to increased selectivity for HDAC6. Docking studies on available HDAC crystal structures were carried out to rationalize the observed selectivity of the compounds. Substitution of the aromatic portion by a thiophene derivative results in high affinity and low cytotoxicity, indicating an improved drug tolerance.

ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE

-

Page/Page column 49-50, (2010/02/11)

The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Amino propynyl benzoic acid building block in rigid spacers of divalent ligands binding to the Syk SH2 domains with equally high affinity as the natural ligand

Dekker, Frank J.,De Mol, Nico J.,Fischer, Marcel J. E.,Liskamp, Rob M. J.

, p. 1241 - 1244 (2007/10/03)

The construction of rigid spacers composed of amino propynyl benzoic acid building blocks is described. These spacers were used to link two phosphopeptide ligand sites towards obtaining divalent ligands with a high affinity for Syk tandem SH2 domains, which are important in signal transduction. The spacer containing two of those rigid building blocks led to a ligand which was as active as the natural ligand, indicating that this building block can be used in the design and synthesis of high affinity divalent constructs that can successfully interfere with crucial protein-protein interactions.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

-

, (2008/06/13)

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 203453-81-0